Syntex' mycophenolate mofetil (MMF)
NDA for the oral immunosuppressant is filed Nov. 9 for prevention of acute kidney transplantation rejection and to treat refractory acute kidney graft rejection, Syntex announces Nov. 22. Syntex parent Roche has submitted registration applications for the drug in 12 European and Scandinavian countries, where it plans to market MMF. The NDA contains data in four clinical trials in approximately 1,650 patients
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth